Actuate Therapeutics, Inc.

Attending the B. Riley Precision Oncology & Radiopharma Conference? Actuate President & CEO, Daniel Schmitt, will participate in a Fireside Chat on Friday, February 28th. Learn more: https://bit.ly/40K4xLj

Today, February 10th at 3:00 p.m. ET, Actuate President & CEO, Daniel Schmitt will participate in the "Voices from the IPO Class of 2024: What's Next?" panel at the BIO CEO & Investor Conference. Find details: https://bit.ly/40K4xLj

Actuate announced that Daniel Schmitt, President & Chief Executive Officer, will participate in the BIO CEO & Investor Conference on Monday, February 10th and the B. Riley Precision Oncology & Radiopharma Conference on Friday, February 28th. For details: https://bit.ly/40K4xLj

Today, we honor the legacy of Martin Luther King Jr. and his vision for a better future. As he said, “Injustice anywhere is a threat to justice everywhere”. May we all continue to work toward justice and equality. #MLKDay #Equality #Justice #Unity

Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer #BioPharmaceuticals #CancerTrials #CancerTherapies https://lnkd.in/exkzkD8e

Whether you are gearing up for year-end festivities, enjoying time with loved ones, or simply taking a moment to pause and reset, we hope this season brings you joy, warmth, and the opportunity to create memories that matter. At Actuate Therapeutics, we are thankful for the continued support of our investors, the dedication of our team, and the trust of our partners who help drive our mission forward. This year has been remarkable thanks to the collective effort and shared commitment to our goals. Wishing everyone a joyful holiday season! #HappyHolidays #HolidaySeason 

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer #BioPharmaceuticals #CancerTrials #CancerTherapies https://lnkd.in/eCnznfEK

As we gather with family and friends to celebrate this season of gratitude, we want to take a moment to express our heartfelt thanks to our team, partners, and shareholders. Your trust, collaboration, and dedication make everything we do possible. This year has been filled with achievements and we are grateful for your continued support every step of the way. We wish you and your loved ones a holiday filled with warmth, joy, and moments to cherish. Happy Thanksgiving from all of us at Actuate Therapeutics! #Gratitude #Thanksgiving #Teamwork #CorporateCommunity

Actuate Therapeutics to be Added to Russell 2000® Index #BioPharmaceuticals #CancerTrials #CancerTherapies #Russell2000 https://lnkd.in/eUz2wQ3U

Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma #BioPharmaceuticals #CancerTrials #CancerTherapies https://lnkd.in/esn7VBvj